Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
Autor: | Klaus Remberger, Helmut Bonkhoff, Thomas Fixemer |
---|---|
Rok vydání: | 2002 |
Předmět: |
Male
Pathology medicine.medical_specialty Urology Apoptosis DNA Fragmentation Adenocarcinoma Biology Neuroendocrine differentiation Prostate cancer Prostate Chromogranins In Situ Nick-End Labeling medicine Humans Neoplasm Staging Prostatic Neoplasms Cancer Chromogranin A Cell Differentiation medicine.disease Immunohistochemistry Neurosecretory Systems medicine.anatomical_structure Oncology Tumor progression biology.protein DNA fragmentation |
Zdroj: | The Prostate. 53:118-123 |
ISSN: | 1097-0045 0270-4137 |
DOI: | 10.1002/pros.10133 |
Popis: | BACKGROUND Neuroendocrine (NE) differentiation has been implicated in prostate cancer progression and hormone therapy failure. It has been shown that prostate cancer cells with NE features lack proliferation activity in vitro and in vivo. The current study reports on the apoptotic status of NE phenotypes in human prostate cancer. METHODS Double-label techniques were used for simultaneous demonstration of the endocrine marker chromogranin A (ChrA) and DNA fragmentation assessed by the terminal transferase-mediated biotinylated 16-desoxy-uridine-tri-phosphate (bio-16-dUTP) nick-end-labeling (TUNEL) assay. The material included primary prostatic adenocarcinoma (n = 18), lymph node metastases (n = 5), bone metastases (n = 2), and recurrent lesions (n = 10) showing NE differentiation at the immunohistochemical level. RESULTS Irrespective of grades, stages, and the degree of NE differentiation, DNA fragmentation was restricted to exocrine (ChrA-negative) tumor cells and was undetectable in most of NE tumor cells expressing ChrA. At least 0.16% of ChrA-positive tumor cells revealed DNA fragmentation assessed by the TUNEL assay. CONCLUSION The present data suggest that the vast majority of prostate cancer cells with NE features escapes programmed cell death. This escape may contribute significantly to their drug resistance and their malignant potential. Prostate 53: 118–123, 2002. © 2002 Wiley-Liss, Inc. |
Databáze: | OpenAIRE |
Externí odkaz: |